drugset / Trial / NCT05456243
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
Timeline
- Start
- 2023-01-30
- Primary completion
- 2026-04-20
- Completion
- 2026-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adipose tissue-derived Mesenchymal Stromal Cells | Cell therapy | 100000 cells/kg | Other |
| Subject | Adipose tissue-derived Mesenchymal Stromal Cells | Cell therapy | 500000 cells/kg | Other |
Indications
No indication recorded.